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Abstract
Affinity chromatography has become an important tool for characterizing biomolecular interactions. The use of 
affinity microcolumns, which contain immobilized binding agents and have volumes in the mid-to-low micro-
liter range, has received particular attention in recent years. Potential advantages of affinity microcolumns in-
clude the many analysis and detection formats that can be used with these columns, as well as the need for only 
small amounts of supports and immobilized binding agents. This review examines how affinity microcolumns 
have been used to examine biomolecular interactions. Both capillary-based microcolumns and short microcol-
umns are considered. The use of affinity microcolumns with zonal elution and frontal analysis methods are dis-
cussed. The techniques of peak decay analysis, ultrafast affinity extraction, split-peak analysis, and band-broad-
ening studies are also explored. The principles of these methods are examined and various applications are 
provided to illustrate the use of these methods with affinity microcolumns. It is shown how these techniques 
can be utilized to provide information on the binding strength and kinetics of an interaction, as well as on the 
number and types of binding sites. It is further demonstrated how information on competition or displacement 
effects can be obtained by these methods.
Keywords: Affinity microcolumns, High-performance affinity chromatography, Biointeraction analysis, Zonal 
elution, Frontal affinity chromatography, Ultrafast affinity extraction
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1. Introduction
Biomolecular interactions make up an important compo-
nent of the many pathways and responses that are present in 
living systems. These interactions include the binding of sub-
strates and co-factors to enzymes, antigens to antibodies, pro-
teins to proteins, and sugars to lectins, as well as the binding 
of small molecules such as hormones and drugs with trans-
port proteins and receptors [1–4]. These interactions can deter-
mine the eventual activity, distribution, excretion, metabolism, 
and effects of a solute or biomolecule in the body. In addition, 
the binding of small molecules with proteins can determine 
the solubility of hydrophobic compounds and can be an im-
portant source of direct or indirect competition between dif-
ferent solutes with the same binding protein (e.g., drug–drug 
interactions) [5–12].
Various techniques can be employed for examining bio-
molecular interactions. These methods include X-ray crys-
tallography, fluorescence spectroscopy, absorption spec-
troscopy, ultrafiltration, equilibrium dialysis, capillary 
electrophoresis, surface plasmon resonance (SPR), and nu-
clear magnetic resonance spectroscopy (NMR) [5, 6, 10, 13–
27]. Two other, related methods that have seen increasing use 
in the study of biomolecular interactions are affinity chroma-
tography and high-performance affinity chromatography 
(HPAC, also known as high-performance liquid affinity chro-
matography or HPLAC) [1–4, 9, 11, 28–30]. These methods 
use a chromatographic column and support that contain an 
immobilized biologically related agent (e.g., a protein or re-
ceptor) as the stationary phase. This immobilized agent can 
then be used to study the binding of injected compounds to 
the column or as a probe to examine the interaction of an in-
jected compound with another binding agent in the mobile 
phase [2, 3]. Various types of columns and formats can be 
used in these experiments [1–3, 9, 11, 31–33]. However, one 
topic that has been of growing interest in the analysis of bio-
molecular interactions is the use of affinity microcolumns for 
such work (i.e., columns containing affinity ligands and with 
volumes in the mid-to-low microliter range) [1, 2, 34–39].
This review examines the developments and applica-
tions that have appeared in the use of affinity microcolumns 
as related to the characterization of biomolecular interac-
tions. First, the basic principles behind affinity chromatogra-
phy and HPAC are described, especially as related to the use 
of these methods in investigating biomolecular interactions. 
The general types of affinity microcolumns that have been 
reported for binding studies are next considered. These mi-
crocolumns range from open-tubular capillaries and packed 
capillaries to small columns based on monoliths or particu-
late supports [2, 4, 40–55]. The various approaches that have 
been used with affinity microcolumns for binding stud-
ies are then discussed. This discussion includes various for-
mats based on zonal elution and frontal analysis [1, 2, 11, 31, 
34, 50–59]. In addition, techniques such as peak decay anal-
ysis, split-peak analysis, ultrafast affinity extraction, and 
band-broadening measurements are discussed [2, 11, 31, 34, 
55]. The principles behind each method are described, along 
with the advantages and possible limitations of these meth-
ods. Various examples are also provided to illustrate the use 
of these techniques with affinity microcolumns. These exam-
ples range from drug–protein interactions (including those 
involving chiral drugs), to antibody–antigen interactions, the 
binding of enzymes with inhibitors, and the interactions of 
lectins with sugars, among others.
1.1. Basic principles of affinity chromatography and 
HPAC
Affinity chromatography is a liquid chromatographic tech-
nique that uses a biologically related binding agent, or “af-
finity ligand”, as the stationary phase to separate or analyze 
sample components [3, 60–64]. This stationary phase can be 
created by covalently attaching, entrapping, absorbing or in 
some other way immobilizing the affinity ligand to a chro-
matographic support [3, 60, 61]. This solid support and the sta-
tionary phase are placed within a column or capillary that can 
then be used for the purification, separation or analysis of tar-
gets capable of binding to the affinity ligand [28, 61–70]. The 
retention and separation of a target from other sample compo-
nents is based on the specific and reversible interactions that 
characterize many biological interactions, such as the binding 
of an antibody with an antigen or a hormone with a receptor 
[1–3, 61–64]. If the interaction is strong (i.e., with an associa-
tion equilibrium constant greater than 105–106 M−1), an elution 
buffer and a change in the pH, temperature, or mobile phase 
composition may be required to remove the target from the 
column [34, 71, 72]. If weaker binding is present (i.e., an asso-
ciation equilibrium constant of 105–106 M−1 or less), it may be 
possible to elute the target under isocratic conditions. This lat-
ter method is sometimes referred to as weak affinity chroma-
tography (WAC) [29, 30]. The variety of elution formats, im-
mobilized ligands, and columns that can be used in affinity 
chromatography has made this method a valuable tool for the 
study of biomolecular interactions [1–3, 31, 51, 57], as will be 
discussed in this review.
In any type of affinity chromatography, the support that 
is used for the immobilized affinity ligand should have low 
non-specific binding to sample components and yet be easy 
to modify for ligand attachment [60–64, 73–76]. Traditional af-
finity chromatography typically employs relatively inexpen-
sive supports and non-rigid materials with low-to-moderate 
efficiencies, such as agarose gels or other carbohydrate-based 
materials [3, 62, 63, 73]. In the method of HPAC, which is the 
type of affinity chromatography utilized with most affinity mi-
crocolumns, the support is a material that has sufficient me-
chanical stability and efficiency for use in HPLC [3, 9, 61, 64, 
73, 74]. This type of support, in turn, tends to provide HPAC 
with better speed and precision than traditional affinity chro-
matography, along with greater ease of automation through 
the use of HPLC systems [1, 4, 59, 61, 73–76]. Possible supports 
for HPAC include particulate materials based on modified sil-
ica or glass, azalactone beads, and hydroxylated polystyrene 
media [1, 3, 61, 73, 74]. Various types of monolithic supports 
have also been considered for use in HPAC and affinity chro-
matography, such as those based on organic polymers, silica 
monoliths, cryogels and modified forms of agarose [4, 73, 75–
82]. The recent interest in monoliths for these affinity-based 
separations is due to several useful features of these supports, 
including their rapid mass transfer properties, low back pres-
sures, and ability to be made in a variety of shapes and sizes 
[4, 73, 75, 76, 79, 82].
The use of affinity chromatography and HPAC for the 
study of biomolecular interactions is sometimes referred to as 
analytical affinity chromatography, quantitative affinity chro-
matography, or biointeraction chromatography [2, 3, 11, 31, 
51–59, 61, 83]. This type of approach either examines the in-
teraction of an applied target with the immobilized affinity li-
gand or uses the affinity ligand to examine interactions of the 
target with another binding agent in the mobile phase (see Fig-
a n a l y s i s  o f  b i o m o l e c u l a r  i n t e r a c t i o n s  u s i n g  a f f i n i t y  m i c r o c o l u m n s :  a r e v i e w   3
ure 1) [2, 31, 61]. A great deal of information can be obtained 
through such experiments. This information can include data 
on the number of interaction sites for the target with a binding 
agent, the equilibrium constants for this process, and the rate 
of the interaction [2, 11, 31, 51, 55, 57, 61, 83, 84]. Data can also 
be obtained on the types of competition the target may have 
with other compounds for interactions with the binding agent, 
and the structure and location of the sites that are involved in 
these interactions [31, 57, 84]. The specific approaches that can 
be used with affinity microcolumns to obtain this information 
are described later in this review.
1.2. Types of affinity microcolumns
A reduction in column size has been of interest in the fields 
of HPLC and chromatographic separations for many years. 
This interest initially appeared due to some common limita-
tions with traditional 10–25 cm × 4.6 mm i.d. HPLC columns, 
such as issues related to high backpressures, solvent consump-
tion, and difficulties in working with small sample volumes 
[85]. To overcome these limitations, work began in the 1970s 
to reduce the size of columns in chromatographic systems and 
to produce various types of small-volume columns [86–89]. 
Examples of approaches that have been used specifically in 
HPAC and affinity chromatography to produce affinity micro-
columns are shown in Figure 2 [34–39].
The first approach for reducing the size of a chromato-
graphic column is to decrease the column’s inner diameter, as 
is illustrated in Figure 2(a). This change is usually accompa-
nied by an increase in column length to maintain or provide 
high efficiency for the system while still giving an overall de-
crease in volume versus traditional columns. This approach 
may involve the use of either open-tubular capillary columns 
or packed capillary columns [85]. Open-tubular capillaries 
that have been used with affinity ligands for binding studies 
have generally had an inner diameter of 100 μm and lengths 
of 30–40 cm, giving total volumes of approximately 2–4 μL 
[35–37]. Packed capillaries that have been used with affinity li-
gands and binding studies have had an inner diameter of up 
to 0.5 mm and a length that ranges from 5 to 15 cm (volumes, 
10–30 μL) [35–37, 41, 42, 46–49, 90–92].
There are several advantages to using the open-tubular or 
packed capillary columns in affinity-based binding studies. 
For instance, the flow rates applied to such columns are usu-
ally quite low (i.e., in the nL/min to μL/min range) and the 
efficiencies can be high, resulting in a significant reduction in 
mobile phase consumption and sample size requirements [85, 
93]. One potential disadvantage is that these capillary columns 
often require specialized equipment that is designed for work 
at low flow rates and high efficiencies (e.g., microbore or nano-
HPLC systems) [41, 43, 85, 93]. However, these columns are at-
tractive for use with on-line detection by mass spectrometry, 
which can provide high sensitivity in detecting small amounts 
of targets and can be used to confirm the identity of a target in 
a mixture of applied compounds [94–96].
Another approach for decreasing the column size is to re-
duce the length of the column, as shown in Figure 2(b). This 
type of design can be employed in separations that do not 
require high efficiencies, such as those based on simple ad-
sorption/desorption mechanisms and selective binding for 
affinity separations involving moderate-to-high strength in-
teractions [3, 58, 60, 61, 97]. Various types of short micro-
columns based on particulate supports or monolithic ma-
terials have been developed for affinity separations and 
binding studies. These columns often have an inner diam-
eter of 2.1 mm or smaller and lengths of 1–5 cm (i.e., vol-
umes less than 35–175 μL). Other possible formats include af-
finity disks, with an inner diameter of 4.6 mm and lengths 
of 1–2 mm [80, 98–100], or sandwich affinity microcolumns, 
with effective lengths as small as 60–250 μm and volumes of 
only 0.2–0.9 μL [101]. A few advantages of using these col-
umns in binding studies are that they are easy to employ 
with traditional HPLC systems, and they require only a small 
amount of support and binding agent. This type of column is 
often capable of withstanding high flow rates, because of its 
low backpressure, and can provide sample residence times in 
the second to millisecond range [38, 40, 102].
One advantage to utilizing either type of affinity microcol-
umn is that they are compatible with a variety of detection ap-
proaches. These detection forms include absorbance, fluores-
cence and near-infrared fluorescence, chemiluminescence, 
matrix-assisted laser desorption/ionization mass spectrome-
try, and electrospray ionization mass spectrometry [35–42, 46–
49, 90, 102]. The small volume of affinity microcolumns [42, 
43, 103] also leads to a significant decrease in the amount of 
support and affinity ligand that are needed for binding stud-
ies when compared to more traditional affinity columns [80, 
97, 101–104]. In a large number of cases, it is possible to reuse 
the same binding agent for many experiments, which further 
helps to improve the precision and to decrease the cost of this 
method [50, 105, 106].
2. Zonal elution and affinity microcolumns
2.1. Principles of zonal elution
Zonal elution is one of the most common formats in HPAC 
and affinity chromatography for studying biomolecular inter-
Figure 1. Two general schemes for the use of HPAC 
and affinity chromatography to study biomolecular 
interactions based on (a) the binding of an applied 
target with the immobilized affinity ligand or (b) use 
of the affinity ligand to examine interactions of the 
target with another binding agent in solution.
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actions. This method was first used with affinity columns in 
1974 [107] and is based on the measurement of peak retention 
times, retention factors or peak profiles. This approach can be 
used to provide information on the strength of binding by a 
target with an affinity ligand and on the competition of the 
target with other compounds for the binding agent [1–3, 11, 
31, 51, 57, 108, 109]. In this type of experiment, a narrow plug 
of the target is injected onto the affinity column under isocratic 
conditions as a detector is used to monitor the elution time or 
profile for the injected analyte. If relatively fast association and 
dissociation kinetics are present on the time scale of the exper-
iment, the retention time of the target should be directly re-
lated to the target’s strength of binding to the immobilized 
agent and the amount of active binding agent that is present in 
the column [2, 11, 30, 31, 109]. Factors that can be altered dur-
ing zonal elution experiments include the mobile phase pH, 
ionic strength and polarity, as well as the temperature, type 
of target, type of affinity ligand in the column, and the pres-
ence of competing or displacing agents in the mobile phase. By 
monitoring the changes in the retention for the target as these 
conditions are varied, detailed data can be obtained on the na-
ture of the interactions between the target and the immobi-
lized binding agent [2, 11, 31, 66, 70, 109–111].
Figure 3(a) shows a typical zonal elution experiment in 
which competition by a mobile phase additive causes a shift 
in the retention of an injected target as these two compounds 
compete for binding sites on an immobilized affinity ligand 
[110]. This example shows the chromatograms generated 
during injections of the site-selective probe R-warfarin onto 
a 2 cm × 2.1 mm i.d. column (volume, 69 μL) that contained 
the immobilized protein human serum albumin (HSA), with 
the drug tolbutamide being placed into the mobile phase as a 
competing agent. In this specific experiment, a decrease was 
observed in the retention of R-warfarin as the concentration of 
tolbutamide was increased, indicating that either direct com-
petition or a negative allosteric effect was occurring between 
these two compounds on HSA [110].
Another format in which zonal elution has been employed 
with microcolumns is shown in Figure 3(b). In this case, the 
immobilized binding agent is used to examine the binding of a 
retained target with a second binding agent that is applied in 
the mobile phase [112]. The column in this particular example 












































Figure 2. Examples of affinity mi-
crocolumns that have been used for 
studying biomolecular interactions, 
including designs based on (a) open-
tubular or packed capillaries and 
(b) short microcolumns or sandwich 
microcolumns.
Figure 3. Examples of the use of zonal elution with affinity micro-
columns in examining biomolecular interactions. In (a) competition 
studies based on zonal elution were carried out using the injection of 
R-warfarin as a site-specific probe onto a microcolumn containing im-
mobilized human serum albumin (HSA) in the presence of various 
concentrations of tolbutamide in the mobile phase. The results in (b) 
show the elution profiles for retinoic acid receptor γ (RARγ) that was 
applied to columns containing apo-cellular retinoic acid binding pro-
tein II (CRABP II) (open circles) or holo-CRABP II (black circles) and in 
the presence of retinoic acid; the gray-shaded circles represent an elu-
tion profile of carbonic anhydrase II (CA II) applied to an apo-CRABP 
II column. Adapted with permission from References [110] and [112].
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cellular retinoic acid binding protein (CRABP) that was initially 
loaded with the target retinoic acid. A sample of a second pos-
sible binding agent for retinoic acid (i.e., retinoic acid receptor 
isoform γ, or RARγ) was then applied to the column and exam-
ined for its elution profile. The presence of a shift in the elution 
profile for this applied binding agent versus a control was used 
to detect an interaction between RARγ and CRABP during the 
transfer of retinoic acid between these binding agents [112].
One advantage of zonal elution is it requires only a small 
amount of target for injection. This method can also examine 
more than one compound in a sample provided there is ad-
equate resolution between the peaks for these compounds or 
a detection format is employed that can distinguish between 
these eluting solutes [57]. As is illustrated in Figure 3(a and b), 
it is also possible with zonal elution to obtain information on 
site-specific interactions, on the competition of two targets for 
the same binding agent [109, 113, 114] or on the competition of 
two binding agents to the same target [115]. As will be demon-
strated in the next few sections, this format can also provide 
information on the strength of binding and the effects that 
changes in the structure of a target or binding agent may have 
on an interaction.
2.2. Estimating binding strength and retention using af-
finity microcolumns
Zonal elution can be used in a variety of ways to obtain in-
formation on biomolecular interactions. An important param-
eter to measure when describing these interactions is the de-
gree or strength of binding that occurs in the system [11, 57, 
116–126]. This information can be obtained from the retention 
time or retention factor (k) for a target that is injected onto an 
affinity column. This retention factor can be calculated from 
the observed elution times through the following relationship,
k =
 tR – tM 
tM                                              (1)
where tR is the observed retention time for the injected target, 
and tM is the column void time.
If relatively fast association/dissociation kinetics and linear 
elution conditions are present during the measurement of the 
retention factor (i.e., the apparent value of k is not affected by 
the amount of injected sample or the flow rate), Equation (2) can 
be used to relate this retention factor to the number of binding 
sites for the target in the affinity column and to the association 
equilibrium constants for the target at these sites [11, 31].
k =
 (Ka1n1 + Ka2 n2 + … + Kannn)mL                      (2)
VM
In this equation, the terms Ka1 through Kan represent the as-
sociation equilibrium constants for the target at each of its bind-
ing sites in the column, n1 through nn are the fractions for each 
type of site in the column, mL is the total moles of all binding 
sites in the column, and VM is the void volume of the column.
The global association equilibrium constant (nKa) for the in-
teraction of a target with the immobilized binding agent can 
be obtained from the numerator of Equation (2), where nKa 
is the summation of the terms Ka1n1 through Kannn. This term 
is directly proportional to k if all of the binding sites have in-
dependent interactions with the target. If the target binds to 
only one type of site on the affinity ligand and in the column, 
the multisite equation in Equation (2) can be rearranged to the 
simpler form that is provided in Equation (3),
k =
 Ka mL                                              (3)
VM
where Ka is the association equilibrium constant for the inter-
action, mL/VM represents the molar concentration of the bind-
ing sites for this interaction, and other terms are as defined 
previously [11, 31].
A few recent studies have examined the ability of short af-
finity microcolumns to be used with zonal elution for esti-
mates of retention factors and binding strength. One set of ex-
periments was carried out at various flow rates for the drugs 
carbamazepine and warfarin when applied to HSA affinity 
microcolumns [116]. These columns contained 4.6 mm i.d. sil-
ica monoliths with lengths of 1–5 mm or were 4.6 mm i.d. col-
umns that were 3 mm in length and that contained HSA im-
mobilized to silica particles. It was found that similar retention 
factors were obtained for warfarin on 3–5 mm long microcol-
umns, and for carbamazepine when the column length ranged 
from 1 to 5 mm. These results indicated microcolumns as 
short as 1–3 mm could be used to provide reproducible reten-
tion factors for drug–protein binding studies that involve sys-
tems with binding constants in the range of 103–106 M−1[116]. 
Additional work was carried out with racemic warfarin and l-
tryptophan on 2.1 mm i.d. HSA microcolumns that contained 
silica particles and that ranged in length from 1 mm to 2 cm. 
This report also indicated that columns as small as only a few 
millimeters in length could be used for zonal elution stud-
ies of drug–protein binding for systems with affinities of 104–
106 M−1[103]. Some loss of precision in retention measurements 
did occur with the use of these small columns and there was a 
greater chance of column overloading [103, 116]. However, it 
was noted that the latter effect could be dealt with by decreas-
ing the sample load or by using reference compounds and re-
tention ratios to adjust for shifts in the retention factors [103].
The fact that the retention factor is related both to the asso-
ciation equilibrium constants and number of binding sites for 
an interaction can be used in a variety of ways. For instance, re-
tention factor measurements of R- and S-propranolol, as model 
drugs, have been used in examining the long-term stability of 
affinity microcolumns that contained high-density lipoprotein 
(HDL) and low-density lipoprotein (LDL) [117–119]. If an in-
dependent estimate is available for the binding capacity (mL), it 
is possible to use this information with measured retention fac-
tors and Equations (2) or (3) to estimate the value of nKa for a 
multi-site system, or Ka for a single-site interaction. This method 
has been used to screen and compare the binding of several 
site-selective probes and sulfonylurea drugs on microcolumns 
containing entrapped samples of HSA or glycated HSA [120]. 
Zonal elution data (with detection based on mass spectrometry) 
has been combined with binding capacities obtained by frontal 
analysis on a packed capillary containing cyclin G-associated ki-
nase for drug discovery; the results were then used to estimate 
and rank the affinity of the kinase for a series of drug fragments 
[123]. A similar method was used to rank the binding constants 
for various drug fragments with the chaperone protein HSP90 
(see Figure 4) [50] and for various carbohydrates in their bind-
ing to hen egg-white lysozyme [54]. It is also possible to use the 
ratio of the retention factor to the known amount of binding 
agent to provide an index that is related to nKa or Ka [126]. This 
technique has been used to compare the activities and proper-
ties for proteins attached within organic-based monoliths that 
were prepared under various polymerization conditions [100].
2.3. Competition and displacement studies using affin-
ity microcolumns
Zonal elution and traditional HPAC or affinity columns 
have often been employed in studying the competition and 
displacement between drugs and other solutes during solute-
protein interactions [11, 31, 45, 57, 84]. In this type of experi-
ment, a competing agent is placed at a fixed concentration in 
6 Z h e n g  e t  a l .  i n  J o u r n a l  o f  C h r o m a t o g r a p h y  B  (2014) 
the mobile phase. A small pulse of a target or site-selective 
probe is then injected onto the column and allowed to interact 
with the immobilized binding agent, as illustrated earlier in 
Figure 3(a). As the target passes through the column, the com-
peting agent may influence binding by the target to the affinity 
ligand through direct competition or allosteric effects. When 
these data are fit to the response that is predicted by various 
models, the types of interactions that are occurring between 
the target, competing agent and immobilized binding agent 
can be determined. This, in turn, can provide information 
on the number of interaction sites, the location of these sites 
(i.e., through the use of site-selective probes), and the binding 
strength at particular sites [31, 127–133].
To illustrate this process, Equation (4) shows the response 
that would be expected between the retention factor for an in-
jected solute and the concentration of a competing agent in the 
mobile phase if these two solutes have direct competition at a 
single type of site on an affinity column [11, 31, 57].
1 =
 Ka,IL VM [I]   +
    VM                                     (4)
                             k       Ka,AL mL         Ka,AL mL 
In this equation, Ka,AL and Ka,IL are the association equilib-
rium constants for the interactions of the immobilized binding 
agent (or affinity ligand, L) with the target/analyte (A) and 
the competing agent (I) at their site of competition. This rela-
tionship predicts that a linear response with a positive slope 
should be obtained for a plot of 1/k versus [I] if A and I have 
a single site of competition. This relationship, in turn, can be 
used to provide the value of Ka,IL for I at its site of competi-
tion with A. If no competition is present between A and I, this 
type of plot will show only random variations in 1/k as [I] is 
increased. If negative allosteric effects or multisite interactions 
are present, deviations from a linear response at low concen-
trations of I should be obtained. If positive allosteric effects are 
present, the value of 1/k should decrease as the concentration 
of I is increased [31, 57].
Plots made according to Equation (4) have been used in 
many recent studies involving affinity microcolumns. An ex-
ample of a plot from a study that used a microcolumn contain-
ing HSA is shown in Figure 5(a)[110]. In this case, a linear re-
sponse was obtained in a plot of 1/k for l-tryptophan as the 
concentration of tolbutamide was varied in the mobile phase. 
This result indicated that tolbutamide had direct competition 
with l-tryptophan at Sudlow site II, the known binding site for 
the latter compound with HSA. The same approach has been 
employed with affinity microcolumns to investigate the com-
petition of various probes with a number of other drugs dur-
ing their interactions with the proteins HSA, glycated HSA, 
and α1-acid glycoprotein (AGP) [44, 45, 109, 110, 113, 130–133]. 
Alternative forms of Equations (3) and (4) have been used 
with other systems [51, 53, 84, 134]. One example was the use 
of competitive zonal elution studies to examine the binding of 
L-fucose, as a mobile phase additive, to immobilized Aleuria 
aurantia lectin as injections of the oligosaccharide LNF III were 
made as a probe [51].
Another type of graph that can be used to analyze both di-
rect competition and allosteric effects using zonal elution data 
is given in Figure 5(b). In this case, a plot of k 0/(k − k 0) versus 
1/[I] is made according to Equation (5), where k 0 and k  are 
the retention factors for injected target A in the absence and 
presence of the competing agent, respectively [135].
                          k0    =
        1         
×
   (     1        +  1 )                (5)                       k − k0     βI→A − 1           Ka,IL [I]
This equation is based on a model where A and I may have 
direct competition at a single site or allosteric interactions 
through two different sites. If an allosteric effect is present, 
the ability of A to bind to L is influenced by the binding of 
I on L, which causes the association equilibrium constant for 
A to change from Ka,AL to K′a,AL. This change can also be de-
scribed by the coupling constant β I→A, which is equal to the 
ratio K′a,AL/Ka,AL. A linear relationship obtained from this plot 
Figure 4. Use of zonal elution and mass spec-
trometry with a 0.5 mm i.d. × 10 cm packed 
capillary containing the N-terminal domain of 
the protein HSP90 to compare the relative re-
tention of four drug fragments (four upper 
chromatograms in each plot), using adenosine 
(bottom chromatogram in each plot) as a ref-
erence. Adapted with permission from Refer-
ence [50].
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can be used to determine the association equilibrium constant 
for I with L (Ka,IL) and the coupling constant, βI→A. A value of 
βI→A between 0 and 1 indicates that a negative allosteric effect 
is present between A and I, while a positive allosteric effect is 
indicated if βI→A is larger than 1. A unique advantage of this 
method is that it can be used to look independently at both di-
rections of an allosteric effect by changing which compound is 
used as A or I in the experiment [135–137].
Plots made according to Equation (5) have been used in 
various studies of biomolecular interactions based on affinity 
microcolumns. Figure 5(b) is one example, which was used to 
determine how binding by R-warfarin to HSA was affected by 
tolbutamide as a competing agent. This plot was used to help 
differentiate between allosteric effects and multi-site binding 
during the interaction of these two solutes on an HSA micro-
column [110]. Equation (5) and similar plots have been utilized 
with microcolumns to study the interactions between various 
fatty acids and sulfonylureas with HSA or glycated HSA [138] 
and allosteric effects that may occur on AGP as it binds to S-
propranolol and warfarin [113].
Experiments based on competition studies and zonal elu-
tion can further be used to determine the location and struc-
ture of binding regions on proteins or other biomolecules. This 
is done by using an injected probe compound that is known 
to bind to a specific site on the protein or affinity ligand, with 
the competing agent in the mobile phase being the compound 
for which possible interactions at this site are being exam-
ined [31]. Such an experiment is illustrated by the examples 
provided in Figure 5. With this technique it is possible to de-
velop a model of both the number of binding regions a solute 
may have with a protein, or other type of affinity ligand, and 
the association equilibrium constants for the solute at each of 
these sites. This technique has been used with microcolumns 
containing HSA or modified forms of this protein to study the 
interactions of drugs such as acetohexamide, tolbutamide, gli-
clazide, glibenclamide and imipramine at Sudlow sites I and II 
or the digitoxin site of this protein [44, 45, 110, 130–133, 139]. 
The same method has been employed to look for common 
binding regions of drugs and drug enantiomers on microcol-
umns that contained AGP [113].
2.4. Other applications of zonal elution with affinity 
microcolumns
Another application of zonal elution is its use in examining 
the effects of various conditions on binding of the target with 
the affinity ligand. Conditions that can be altered during such 
studies include the temperature, pH, ionic strength and con-
tent of the mobile phase [31, 66, 70, 111, 140–142]. For instance, 
varying the polarity of the mobile phase can be used to alter 
non-polar interactions between a target and a protein, and/or 
change the conformation of the protein or the target. This is 
a common tactic used with chiral stationary phases based on 
proteins to alter their retention and stereoselectivity [40, 140, 
141, 143]. Some examples are provided in Figure 6, in which 
an organic modifier was used to increase the speed of chiral 
separations for R/S-warfarin and d/l-tryptophan on a 4.6 mm 
i.d. × 10 mm microcolumn that contained HSA immobilized to 
an organic monolith [100].
It is also possible to use zonal elution to examine the effects 
of changes in the structure of a target on its interactions with a 
given binding agent. This general approach can involve creat-
ing a quantitative structure–retention relationship (QSRR), in 
which the retention factors for a set of structurally related mol-
Figure 5. Results of zonal elution competition studies on HSA micro-
columns examining the change in retention of (a) l-tryptophan as a 
probe for Sudlow site II and (b) R-warfarin as a probe for Sudlow site 
I in the presence of tolbutamide as a competing agent. The solid lines 
show the best-fit responses that were obtained when fitting (a) Equa-
tion (4) or (b) Equation (5) to the data. These results were obtained un-
der similar or identical conditions to those used in Figure 3(a). Repro-
duced with permission from Reference [110].
Figure 6. Chiral separations for (a) R- and S-warfarin and (b) d- and l-
tryptophan on a 4.6 mm i.d. × 10 mm microcolumn containing HSA 
immobilized to a monolith based on a co-polymer of glycidyl meth-
acrylate and ethylene glycol dimethacrylate. The mobile phase was 
pH 7.4, 0.067 M phosphate buffer that contained 0.5% 1-propanol and 
the flow rate was (a) 2.0 mL/min or (b) 3.0 mL/min. Reproduced with 
permission from Reference [100].
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ecules are measured on an affinity column under otherwise 
similar temperature and mobile phase conditions. These data 
are then compared to various factors that describe the struc-
tural components of the applied targets to see which of these 
factors most affected the retention [35, 144–147]. This tech-
nique has been used with traditional HPAC columns to in-
vestigate the skin permeation of several organic molecules 
through the use of a column containing immobilized keratin 
[144], to characterize binding of HSA to benzodiazepine drugs 
[145–147], and to examine the interactions of AGP with anti-
histamines, beta-adrenolytic drugs, and other agents [148–
154]. In work with affinity microcolumns, the same general 
method has been used to compare the binding of various sul-
fonylurea drugs at both Sudlow sites I and II of HSA [155].
A related approach is to use affinity microcolumns to see 
how biomolecular interactions change as variations are made 
in the structure of the immobilized binding agent [156–158]. 
This tactic has been used to see how the non-enzymatic gly-
cation of HSA, as occurs during diabetes [129, 159], may alter 
the binding of this protein to various drugs and solutes. These 
studies have used R-warfarin, l-tryptophan and digitoxin as 
probes (i.e., for Sudlow sites I and II and the digitoxin site of 
HSA, respectively), along with samples of glycated HSA that 
had various known levels of modification. The results for in 
vitro glycated samples indicated that changes in the affinities 
for sulfonylurea drugs and l-tryptophan did occur as the level 
of glycation for HSA was increased and that these changes 
differed between solutes and the binding site that was exam-
ined [45, 110, 130–133]. Similar effects were seen in affinity mi-
crocolumns that contained in vivo glycated HSA that was ob-
tained from several patients with diabetes [44].
Affinity microcolumns and zonal elution have also been 
used in the high-throughput screening of compound fragment 
mixtures based on WAC and mass spectrometry (WAC-MS). 
This method has been utilized to screen the binding of drugs 
to albumin [32] and binding of compound fragments to prote-
ase [52, 160] or kinase targets [123]. As an example, one recent 
study showed that 111 fragments could be screened on a cap-
illary column containing the protein HSP90, as illustrated ear-
lier in Figure 4. The results of WAC were found to show good 
agreement with data obtained by NMR, SPR, and isothermal 
titration calorimetry, as well as crystallographic data [50].
3. Frontal analysis and affinity microcolumns
3.1. Principles of frontal analysis
Frontal analysis, or frontal affinity chromatography (FAC), is 
another common technique that is used in HPAC and affin-
ity chromatography to study biomolecular interactions. In this 
method, a target solution is continuously applied to a column 
while the amount of target that elutes from the end of the col-
umn is monitored [57, 109, 161]. As the target binds to the im-
mobilized affinity ligand, the column begins to become satu-
rated and the amount of the target that elutes from the column 
increases with time or with the volume of applied target [31]. 
The result is the formation of a breakthrough curve, as is illus-
trated in Figure 7(a) for R-propranolol that was applied to an af-
finity microcolumn containing HDL as the binding agent [117].
Frontal analysis was first used with traditional affinity col-
umns in the mid-to-late 1970s [162–164]. In the early 1990s 
this technique was used with HPAC to study drug–pro-
tein binding [165]. Over the last 10–15 years, this method has 
been utilized with various types of affinity microcolumns and 
capillary columns for binding studies; this includes the com-
bination of this method with mass spectrometry, giving a 
method known as frontal affinity chromatography–mass spec-
trometry (or FAC-MS) [46, 90–92, 117, 166].
There are several advantages, and potential disadvantages, 
to using frontal analysis versus zonal elution to examine a bio-
molecular interaction. For instance, frontal analysis is easier to 
use in providing independent information on both the over-
all number of binding sites for an interaction and the equi-
librium constants for these interactions [11, 31]. On the other 
hand, zonal elution competition experiments, as discussed in 
the previous section, are more convenient for identifying in-
teraction sites and measuring binding constants specifically at 
these sites. Frontal analysis tends to require more solute than 
zonal elution, but column overloading effects are not a prob-
lem in frontal analysis because column saturation is actually a 
desirable feature for at least part of such an experiment [31]. In 
addition, the higher amounts of a target that are typically used 
in frontal analysis can make it easier to detect an interaction 
with this method than when using zonal elution [31, 46, 90].
3.2. Estimating binding strength and number of sites us-
ing affinity microcolumns
An important application of frontal analysis is the use of this 
approach to obtain information on both the overall number 
of interaction sites an applied target has with an immobilized 
affinity ligand and the equilibrium constants for these inter-
actions. Data can be obtained for this purpose by applying to 
the affinity column a wide range of target concentrations, as 
demonstrated earlier in Figure 7(a). The mean position of the 
breakthrough curve is then measured at each applied con-
centration of the target, and the resulting data are fit to var-







































Figure 7. (a) Typical chromatograms (i.e., breakthrough curves) ob-
tained for a frontal analysis experiment, as obtained here for the ap-
plication of various solutions R-propranolol to a 5 cm × 2.1 mm i.d. 
column containing immobilized high-density lipoprotein (HDL). (b) 
Analysis of frontal analysis data obtained for R-propranolol on the 
HDL column by fitting to the results to a model based on a combina-
tion of a saturable binding site and a non-saturable interaction. Repro-
duced with permission from Reference [117].
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instance, either Equation (6) or (7) can be used to describe a 
system in which a single-site interaction is occurring between 
the target and the immobilized binding agent [31].
                                  mL,app 
 
=
  mL Ka[A]   (6)
                                                  1 + Ka[A] 
                                      1      =         1        +   1       (7)                                  mL,app       KamL[A]      mL
In these equations, mL,app is the apparent moles of target that is 
required to reach the mean position of the breakthrough curve 
at a given concentration of the applied target or analyte ([A]). 
The term Ka is the association equilibrium constant for this 
process, and mL is the total moles of active binding sites that 
are involved in this interaction. By using a non-linear fit of 
mL,app versus [A] to Equation (6), or a linear fit of 1/mL,app ver-
sus 1/[A] to Equation (7), the values of both Ka and mL can be 
obtained for this system. If multiple types of binding sites or 
interactions are present, alternative binding models and equa-
tions can also be fit to the data [31, 167, 168].
An example of this type of analysis when using an affinity 
microcolumn is provided in Figure 7(b). This example shows 
the use of a model based on both a saturable binding site and a 
non-saturable interaction to describe the interactions of R-pro-
pranolol with HDL [117]. This approach has been employed 
with small columns in HPAC and with other drugs and serum 
agents, such as the binding of S-propranolol and verapamil 
with HDL [117], the interactions of R- and S-propranolol with 
LDL [118], the binding of drugs with AGP [113, 169–173], and 
the interactions of various drugs and solutes with HSA or 
modified HSA [44, 45, 108, 110, 130–133, 139]. Frontal analy-
sis was used to determine the binding capacity of adenosine 
on a packed capillary containing cyclin G-associated kinase 
[123], and FAC-MS has been used with open-tubular capil-
laries containing peroxisome proliferator-activated recep-
tors to compare and rank the binding of the agents to various 
urediofibrate-like dual agonists [36]. Capillary monolith col-
umns containing lectins or enzymes have been employed with 
FAC-MS to examine the equilibrium constants of applied tar-
gets with these affinity ligands [41, 46, 48]. FAC-MS has also 
been coupled with capillary columns for the high throughput 
screening of enzyme inhibitors, oligosaccharides, and other 
targets for immobilized binding agents [166].
The effect of column size on the results of frontal analysis 
experiments has been recently examined for systems with low-
to-moderate affinity interactions [103]. This work used HSA as 
the immobilized binding agent and warfarin as a model tar-
get (i.e., a drug with single-site binding to HSA and a well-
characterized affinity for this site). Table 1 shows the results 
that were obtained for 2.1 mm i.d. microcolumns with lengths 
ranging from 2 cm down to only 1 mm and packed with sil-
ica particles. Each of these columns gave a good fit for their 
frontal analysis data to a single-site model, and the measured 
binding capacity decreased in proportion to the total column 
volume. It was also found that all of these columns gave asso-
ciation equilibrium values that were in good agreement with 
literature values; however, the results obtained for the short 
columns did have less precision that those obtained for the 
longer columns. The main benefit of using the shorter columns 
was the much smaller amount of immobilized binding agent 
that they required and their shorter residence times. These fea-
tures made these affinity microcolumns appealing for future 
use in the high-throughput screening of drug candidates and 
in rapid studies of drug-protein binding [103].
3.3. Competition and displacement studies using affin-
ity microcolumns
Frontal analysis, and especially FAC-MS, has also been used to 
examine the competition between potential targets and immo-
bilized binding agents on affinity microcolumns [36, 37, 57]. In 
this type of study, a competing agent is added with the target 
in the mobile phase. The resulting chromatograms are then an-
alyzed by measuring the change in breakthrough time or vol-
ume of the target as a function of the competing agent’s con-
centration (see Figure 8) [37]. Direct competition or negative 
allosteric effects between the target and competing agent can 
be detected when the breakthrough time decreases with an in-
crease in the competing agent’s concentration. Alternatively, 
positive allosteric effects can lead to a larger breakthrough 
time for the target as the concentration of the competing agent 
is increased [57].
It is possible to obtain a qualitative ranking of the strength 
of displacing agents based on chromatograms like those in 
Figure 8, but a quantitative analysis of such data is possible as 























Table 1. Effect of column length on the association equilibrium constants (Ka) and binding capacities (mL) measured by frontal analysis for warfa-
rin on affinity microcolumns containing immobilized human serum albumin.a
Column length (mm) Column volume (μL) mL (nmol) Ka (×105 M−1) Relative activityb
 20 69 27.6 (±0.2) 2.0 (±0.1) 1.00 (reference)
 10 35 9.7 (±0.2) 3.0 (±0.1) 0.68 (±0.02)
 5 17 4.1 (±0.3) 3.4 (±0.3) 0.58 (±0.05)
 3 10 3.8 (±0.3) 2.3 (±0.1) 0.92 (±0.08)
 2 6.9 2.6 (±0.3) 2.1 (±0.2) 0.92 (±0.08)
 1 3.5 1.2 (±0.1) 2.6 (±0.8) 0.83 (±0.08)
a. The inner diameter of all the columns was 2.1 mm. The Ka and mL values provided are the average results obtained over flow rates ranging from 
0.5 or 1.0 to 2.0 mL/min. The results in this table are based on data provided in Reference [103].
b. The relative activities were determined by comparing the specific activity measured for each column to the specific activity measured for the 
2 cm long column.
Figure 8. Example of a displacement experiment using frontal analy-
sis and detection based on mass spectrometry. These chromatograms 
show the effects of adding (B) vitexin, (C) naringenin, (D) apigenin, (E) 
quercetin, (F) kaempferol, or (G) luteolin to a solution containing (A) 
quercetin as the target and applied to a 30 cm × 100 μm i.d. open-tu-
bular capillary column containing an immobilized form of the histone 
decarboxylase SIRT6. Adapted with permission from Reference [37].
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interactions between a competing agent (I) and the target dur-
ing such an experiment [36, 37, 174–176].
                          VR − Vmin =
          P  (8)
                                                (Kd,IL + [I]) 
In this expression, Kd,IL is the dissociation equilibrium constant 
of the competing agent with the immobilized affinity ligand, 
[I] is the concentration of the competing agent, VR is the break-
through volume of the target, and Vmin is the breakthrough vol-
ume of the target when the interaction being examined is com-
pletely suppressed (i.e., as can be determined by running the 
target with a high concentration of the competing agent). The 
term P is the product of the number of active binding sites and 
the term Kd,IL/Kd,AL, where Kd,AL is the dissociation equilibrium 
constant for the target (or analyte) with the immobilized ligand.
Several reports have used Equation (8) or equivalent rela-
tionships in displacement studies based on FAC-MS and af-
finity microcolumns [36, 37]. The example in Figure 8 utilized 
an open-tubular capillary that contained the histone deacety-
lase SIRT6. This column was used with FAC-MS to estimate 
the dissociation equilibrium constants for several structurally 
related flavonoids based on their ability to displace querce-
tin, a known inhibitor for SIRT6 [37]. Open-tubular capillaries 
containing the ligand binding domains of peroxisome prolif-
erator-activated receptors were employed in a similar manner 
to examine the interactions and rank the affinities of ureidofi-
brate-like dual agonists with these columns [36].
3.4. Other applications of frontal analysis with affinity 
microcolumns
As mentioned earlier, changes in factors such as the tempera-
ture or mobile phase can alter a biomolecular interaction. Like 
zonal elution, frontal analysis can be employed to see how 
such changes may alter an interaction. One advantage of us-
ing frontal analysis for this purpose is it can be used to inde-
pendently examine how both the affinity and moles of binding 
sites are affected by a change in the temperature or reaction 
conditions [31, 143]. As an example, the effect of temperature 
on the binding for R- and S-propranolol with HDL and LDL 
has been studied using affinity microcolumns [117–119]. The 
results showed that a change in temperature had little effect 
on either the association equilibrium constants or the binding 
capacities between these drugs and binding agents [117–119].
Frontal analysis has also been used to examine the binding 
of solutes to modified proteins. This technique has been uti-
lized to compare the binding of several solutes to HSA that 
has been modified to various extents by glycation [44, 45, 130–
133]. Both the affinities and binding capacities for targets such 
as warfarin, l-tryptophan and sulfonylurea drugs were con-
sidered in going from normal HSA to in vitro [45, 130–133] or 
in vivo [44] samples of glycated HSA. Warfarin and l-trypto-
phan were found to bind to both sets of proteins through a sin-
gle-site interaction [122, 131], but the sulfonylurea drugs inter-
acted through a two-site model that involved a set of high and 
low affinity sites [130]. The results indicated that the glycation 
of HSA could affect the affinity of this protein for l-trypto-
phan and some of the sulfonylurea drugs, but no appreciable 
change was noted for warfarin under modification conditions 
similar to those seen in diabetes [44, 131].
Affinity microcolumns and frontal analysis have been 
used in a growing number of reports for the high-throughput 
screening of compound mixtures with regards to their binding 
to biological ligands. This research has used FAC-MS to rank 
and measure the binding of several applied compounds in a 
single experiment, as demonstrated with columns that have 
contained enzymes, antibodies, lectins or human estrogen re-
ceptor β [166]. FAC-MS and such columns have been em-
ployed to screen the binding of enzyme inhibitors, oligosac-
charides and peptide libraries [49, 166, 175, 176]. For instance, 
an open-tubular capillary containing an immobilized nuclear 
receptor was used in FAC-MS to determine the relative affini-
ties for a series of chiral fibrates with this receptor [35].
4. Other methods for studying biomolecular 
interactions using affinity microcolumns
4.1. Peak decay analysis
Peak decay analysis is a method for kinetic analysis that is par-
ticularly well-suited for use with affinity microcolumns [177–
180]. This method was first described in 1987 [177] and was 
originally based on the application of a target to an immobi-
lized binding agent, followed by the application of a high con-
centration of a competing agent to displace the retained an-
alyte. This early work used a column containing the lectin 
concanavalin A to determine the dissociation rate constant 
for the sugar 4-methylumbelliferyl α-d-mannopyranoside 
from this binding agent, with 4-methylumbelliferyl α-d-
galactopyranoside acting as a competing agent to avoid re-
binding by the target sugar during the elution process [177]. It 
was shown in later work with weak-to-moderate affinity sys-
tems that a modified version of this method can be used in 
which no competing agent is required [178–180].
In a typical peak decay experiment, the elution step is carried 
out at a flow rate, column size and/or competing agent concen-
tration that prevents the displaced analyte from rebinding to the 
column [31, 177–180]. The flow rate, support material and col-
umn size also need to be selected to provide mass transfer be-
tween the flowing and stagnant regions of the mobile phase that 
is faster than the rate of dissociation for the target from the im-
mobilized binding agent. If these conditions are met, the result-
ing elution profile can be used to obtain the dissociation rate 
constant for the target from the binding agent [31, 177].
Once the elution profile has been collected for the target, a 
plot can be made of the logarithm of the peak response versus 
time. If dissociation of the target from the immobilized bind-
ing agent is the rate-limiting step for elution and no rebinding 
of the target occurs to the column, Equation (9) can be used to 
determine the dissociation rate constant for the target from the 
immobilized binding agent [31, 177].
                         ln ( dmEe ) = ln (mE0 kd) − kd t   (9)                                  dt
In this equation, the mE0 is the initial moles of target that were bound to the column, mEe is the moles of the target that elute 
in the mobile phase at time t, and kd is the dissociation rate 
constant of the target from the immobilized binding agent. 
Under the given conditions, Equation (9) predicts that there 
should be a linear relationship between the natural logarithm 
of the elution peak, ln(dmEe/dt), and the time allowed for tar-
get elution, t. The dissociation rate constant can then be ob-
tained from the slope of the resulting curve [2, 31, 177].
An example of peak decay experiment is shown in Figure 9, 
in which the dissociation of nortriptyline is examined by using 
the peak decay method with an AGP microcolumn contain-
ing silica particles [180]. This particular example is based on a 
non-competitive peak decay method, in which short microcol-
umns and high flow rates, rather than a competing agent, are 
used to reduce the possibility of a target rebinding to the col-
umn. This method has recently been modified for use with af-
finity microcolumns containing silica monoliths to study the 
dissociation rates for a large set of drugs (i.e., warfarin, diaz-
epam, imipramine, acetohexamide, tolbutamide, amitripty-
line, carboplatin, cisplatin, chloramphenicol, nortriptyline, 
quinidine and verapamil) with HSA [173, 180]. This approach 



























has also been applied with affinity microcolumns that contain 
AGP to estimate the dissociation rate constants of this protein 
for amitriptyline and lidocaine, as well as nortriptyline [180].
Another variation of the peak decay method occurs when 
a change in a factor such as pH is used to cause release of the 
target and to prevent rebinding of this target to the column. 
For example, this method was used to determine the dissoci-
ation rate constants of the herbicide 2,4-dichlorophenoxyace-
tic acid (2,4-d), and related solutes, from immobilized antibod-
ies at various pH values and flow rates. This information was 
then used to help in the design and optimization of an HPAC 
system for the analysis of 2,4-d and related herbicides in water 
samples [179]. The peak decay method has also been utilized 
to study the elution kinetics of thyroxine from columns con-
taining immobilized antibodies or aptamers [181] and to ex-
amine the dissociation of immunoglobulin G-class antibodies 
from protein G (i.e., an antibody-binding protein) [113].
4.2. Ultrafast affinity extraction
Another method for examining biomolecular interactions and 
using microcolumns is ultrafast affinity extraction [38, 39, 80, 
101, 102, 104, 182]. This approach examines the interaction of 
a target and a binding agent that is in solution but uses an af-
finity microcolumn to probe the non-bound, or free, fraction 
of the target that remains. In this technique, the target is in-
jected in the presence or absence of the soluble binding agent 
onto a microcolumn that contains an affinity ligand that can 
selectively retain the target in its free form. This affinity ligand 
may be a specific agent, such as an antibody for a given target 
[80, 101, 182]. Alternatively, the affinity ligand may be a more 
general binding agent, such as a serum transport protein like 
HSA for the retention of various drugs [38, 39, 102, 104]. If the 
flow rate and column conditions are selected correctly, the res-
idence time for the sample in the column can be made small 
enough that no significant dissociation will occur of the target 
from the soluble binding agent as the sample passes through 
the column. For instance, affinity microcolumns have been 
used to produce sample residence times down to the low-to-
mid millisecond range for this method [38, 40, 104].
This type of study is carried out by using the general 
scheme shown in Figure 10, in which an affinity microcol-
umn containing HSA is used to separate the free and protein-
bound fractions of a drug or small target in a sample [38]. In 
this example, the protein-bound fraction of the target and the 
protein in the sample will elute first in the non-retained frac-
tion. This is followed later by elution of the retained free frac-
tion of the target. The free fraction of the target can then be 
determined by comparing the measuring retained peaks for 
the target in the presence or absence of the soluble binding 
agent. This information, in turn, can be used to determine the 
association equilibrium constant for the interaction of the tar-
get with the binding agent in the sample if the binding agent’s 
total concentration is also known. For instance, Equations 
(10) and (11) describe the relationship between the observed 
free fraction (f) and the association equilibrium constant (Ka) 




 CA − [A − P]                                     (10)
                                                      CA 
Ka =
                    [A − P]                                       (11)
                                    (CA − [A − P]) (CP − [A − P])  
In these equations, CA is the total concentration of the target 
in the original sample, CP is the total concentration of soluble 
binding agent, and [A – P] is the concentration of the target-
binding agent complex in the original sample [38, 40].
One advantage of free fraction analysis is its ability for 
rapid measurements. This is partly due to the fact that sam-
ple residence times in the range of only a few hundred milli-
seconds or less are used to minimize the possibility that the 
target may dissociate from the soluble binding agent during 
the analysis [38, 40, 104]. It has been shown that the results ob-
tained by this technique are comparable to those found with 
the reference methods such as ultrafiltration and equilibrium 
dialysis, among others [38–40, 57, 182]. Furthermore, because 
this method directly examines the interactions between a tar-
get and a soluble binding agent, it is not subject to the immo-
bilization effects that can occur with other affinity methods if 
improper conditions are used to couple the binding agent to 
the support [38, 39, 80, 101, 102, 104, 182].
Figure 10. General scheme for the use of ultrafast affinity extraction with an HSA microcolumn to separate the free and protein-bound fractions of 
a drug or solute in an injected sample. Reproduced with permission from Reference [38].
Figure 9. Typical results for a peak decay experiment, as obtained for 
the injection of nortriptyline at flow rates of 5, 7 or 9 mL/min (from 
right-to-left) on a 1 mm × 4.6 mm i.d. microcolumn containing immo-
bilized AGP. This example includes the (a) elution profiles and (b) nat-
ural logarithm of these elution profiles for a 100 μL injection of 20 μM 
nortriptyline. Reproduced with permission from Reference [180].
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Several recent studies have used ultrafast affinity extraction 
to examine biomolecular interactions. For instance, this method 
has been used with immobilized antibodies and fluorescence 
detection to measure the free drug fraction in mixtures of war-
farin and HSA [104]. This technique has also been combined 
with a displacement immunoassay to measure the free fraction 
of thyroxine and phenytoin in clinical samples by using chemi-
luminescence or near-infrared fluorescence detection [39, 102, 
182]. Use of this scheme to estimate association equilibrium con-
stants has been shown with HSA and drugs such as R- or S-war-
farin, S-ibuprofen and imipramine to give good agreement with 
the values obtained by other methods [38]. In a recent study, a 
multi-dimensional HPAC system was developed by combining 
ultrafast affinity extraction with a chiral stationary phase to si-
multaneously examine the free fraction of warfarin enantiomers 
in serum or drug–protein mixtures. The binding constants that 
were estimated for R- and S-warfarin with HSA or serum by 
this approach also gave results comparable to those of a refer-
ence method and literature values [40].
4.3. Split-peak analysis
The split-peak method is another technique that is readily 
employed with affinity microcolumns. This is a method of ki-
netic analysis that is based on the fact that there is a probabil-
ity during a chromatographic separation that a small fraction 
of target will elute non-retained from the column without in-
teracting with the stationary phase. In HPAC, this method can 
be used to study the rate of association of a target with an im-
mobilized binding agent by using column size and flow rate 
conditions that promote the probability of this effect [97].
The following equation describes how the relative size of the 
non-retained target fraction ( f ) will change with the flow rate 
when a small amount of target is injected onto such a column [97].
                                   
−
   1    = F (   1    +     1   )   (12)                                       ln f           k1Ve     kamL 
In Equation (12), F is the flow rate, mL is the moles of active and 
immobilized binding agent in the column, and Ve is the excluded 
volume (i.e., the volume of flow mobile phase) in the column. 
The term k1 is the forward mass transfer rate constant for the tar-
get as it moves from the flow mobile phase region to the stagnant 
mobile phase at the surface or within the pores of the support, 
and ka is the association rate constant for the target as it binds to 
the affinity ligand in the column. This equation shows that the 
rate-limiting step in the binding of the target to the column can 
be either mass transfer in the mobile phase, as represented by the 
term 1/(k1Ve), or adsorption to the affinity ligand, as represented 
by 1/(kamL). Thus, information can be obtained on the interaction 
of the target with the affinity ligand if the term 1/(kamL) is made 
comparable to or larger than 1/(k1Ve) [97].
The results for a typical series of split-peak experiments are 
shown in Figure 11 [97]. As part of this process, the peak ar-
eas for the retained and non-retained fractions of an injected 
target are first made over a range of flow rates and at vari-
ous sample concentrations. A plot of −1/ln(f) versus F is then 
made according to Equation (12) at each sample concentration, 
and the measured slopes are extrapolated to an infinitely di-
lute sample [97, 183, 184]. This slope is then compared to inde-
pendent estimates of the mass transfer contribution, 1/(k1Ve), 
by injecting the same analyte on an inert control column or on 
a column with rapid association kinetics. If a separate estimate 
of mL is also available, this process allows 1/(kamL) and ka to be 
obtained [97]. A key advantage of this approach is it requires 
only peak area measurements. The main disadvantage is this 
method tends to be limited to targets and binding agents with 
relatively slow dissociation kinetics, which generally corre-





























Several applications have appeared for the split-peak method 
using affinity microcolumns. For instance, this technique was 
originally used to study and compare the binding kinetics of 
rabbit immunoglobulin G (IgG) on various columns contain-
ing protein A that was immobilized by different methods (see 
Figure 11) [97]. Based on this data it was possible to obtain 
the association rate constant for IgG with each protein A sup-
port [97, 183], which later made it possible to optimize and use 
one of these supports for the analysis of human IgG in clin-
ical samples [185]. This method has also been utilized to de-
termine the apparent association rate constants for IgG on col-
umns containing only protein A or protein G, or a mixture of 
these two antibody-binding agents [184].
A modified form of the split-peak method has been re-
ported for the case where there is non-linear elution and an 
adsorption-limited rate for target retention [184, 186–190]. 
This modified approach has been used to examine the asso-
ciation kinetics of HSA with a variety of antibody-based sys-
tems [188–190]. In addition, this non-linear method has been 
utilized to help model and describe the behavior of chromato-
graphic-based competitive binding immunoassays [186, 191, 
192]. Recent work has also expanded this method for use in 
a frontal analysis format to examine the binding of herbicides 
with immobilized antibodies [179] and thyroxine with immo-
bilized antibodies or aptamers for this hormone [181].
4.4. Band-broadening studies and peak profiling
There are several methods for studying the kinetics of a bio-
molecular interaction based on the use of HPAC and affinity 
chromatography [11]. For example, systems that have low-to-
moderate strength interactions (i.e., Ka < 106 M−1) can be ex-
amined through the use of band-broadening measurements 
[11, 31]. This technique, known as the plate height method, in-
volves a measurement of the total plate height at several flow 
rates for a target on a control column containing no binding 
agent and on an affinity column that contains the immobi-
lized binding agent of interest. These data are then used to de-
termine the plate height contribution due to stationary phase 
mass transfer (Hk). This term is of interest because it is related 
Figure 11. Analysis of split-peak data according to Equation (12) for 
injections of rabbit immunoglobulin G (IgG) onto protein A columns 
prepared by various immobilization methods and supports. The con-
ditions for each plot were as follows: Schiff base method, 500 Å pore 
size silica, 22 μg IgG (○); Schiff base method, 500 Å pore size support, 
11 μg IgG (●); Schiff base method, 50 Å pore size support, 15 μg IgG 
(▲); carbonyldiimidazole method, 500 Å pore size support, 2.7 μg IgG 
(■); and ester/amide method, 500 Å pore size support, 8.2 μg IgG (♦). 
Reproduced with permission from Reference [97].
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to the dissociation rate of the target’s interaction with the im-
mobilized binding agent, as indicated by Equation (13).
Hk =
       2uk                                               (13)
                                               kd (1 + k)2
In Equation (13), u is the linear velocity of the mobile phase 
in the column, k is the retention factor of the injected target, 
and kd is the dissociation rate constant between the target and 
immobilized binding agent. According to this relationship, a 
plot of Hk versus (uk)/(1 + k)2 should give a linear relationship 
with a slope that can provide the value of kd [31].
The plate height method has been applied with traditional 
HPAC columns to study the association and dissociation ki-
netics of R/S-warfarin and d/l-tryptophan with HSA [121]. 
This method has also been used to examine the changes in 
binding of R/S-warfarin and d/l-tryptophan that occur as a 
result of the change in reaction conditions (e.g., pH, tempera-
ture, and organic modifier content of the mobile phase) [121]. 
Although this method has not been used directly with micro-
columns, preliminary work with both silica particles and silica 
monoliths indicates that plate height measurements suitable 
for this type of work can be carried out by using 2.1 mm i.d. 
columns as small as 1–5 mm in length [103, 116].
Peak profiling is a variation on this general scheme which 
directly combines band-broadening data for a target on a con-
trol column and an affinity column, as determined under lin-
ear elution conditions. This method was first proposed in 1975 
[193] and involves a determination of the retention times and 
total plate heights on the affinity column for the target and a 
non-retained solute (or for the target on a control column, in 
the latter case). Such measurements have been made at a sin-
gle flow rate to find the value of kd for the interaction of the 
target with an immobilized binding agent, or these measure-
ments can be made at multiple flow rates [44, 193–198].
One way that peak profiling data can be analyzed is ac-
cording to Equation (14),
HR − HM =
       2uk        =    Hk                            (14)                                               kd (1 + k) 2
where HR is the plate height for the target on the affinity col-
umn and HM is the plate height of the non-retained solute on 
the same column, or for the target on an inert control column. 
The other terms are the same as defined for Equation (13). It 
is possible with this new relationship to either calculate the 
value of kd at a single flow rate or to make a plot of (HR − HM) 
versus (uk)/(1 + k) 2 for data obtained at several flow rates and 
to use the slope of the resulting line to get kd [44]. Both Equa-
tions (13) and (14) are for a situation in which the target has 
only a single type of interaction with the affinity column. Re-
cently, an expanded set of equations have been described for 
use with systems that have multi-site interactions with both 
the support and an affinity ligand [198].
The peak profiling method has been applied to several 
systems in recent studies. For instance, this method was 
used to examine the dissociation rate of l-tryptophan from 
immobilized HSA, giving a value for kd that was consis-
tent with those obtained by other methods [195]. The multi-
site method for peak profiling has been used to determine 
the dissociation rate constants for carbamazepine and imip-
ramine with HSA (see Figure 12) [194]. A modified form of 
this technique has also been employed to compare the disso-
ciation rate constants of chiral metabolites for the drug phe-
nytoin with HSA [194]. As work continues in the creation of 
improved affinity microcolumns, including the use of capil-
laries [35, 36, 46–48, 92, 129] or monoliths [4, 73, 75, 76], it is 
expected that peak profiling can also be applied to separa-
tions that employ such columns.
5. Conclusions
This review discussed various methods based on affinity mi-
crocolumns for the study of biomolecular interactions. These 
microcolumns, which have typical volumes in the mid-to-low 
microliter range, contain an immobilized binding agent for 
the selective retention of target compounds. In binding stud-
ies, these columns can be used to examine the target’s inter-
action with the immobilized binding agent or can use this 
immobilized agent to probe interactions of the target with sec-
ondary binding agents in the mobile phase. Microcolumns can 
be made by decreasing the inner diameter and increasing the 
column length, as is used in affinity open-tubular capillaries 
or packed capillaries (i.e., for separations requiring a high ef-
ficiency), or by reducing the length of the column (i.e., as can 
be used in separations that do not require high efficiencies). 
Either type of microcolumn can be employed with many de-
tection formats and can lead to a significant decrease in the 
amount of binding agent and support that are needed versus 
traditional columns for affinity chromatography or HPAC.
Affinity microcolumns can be used in many formats and 
can provide a wide range of information on biomolecular in-
teractions. Two techniques that are commonly used in these 
studies are zonal elution and frontal analysis. With these 
methods, it is possible to determine the degree of binding 
between a target and binding agent, to measure the equilib-
rium constant for this interaction, and to estimate the number 
of binding sites. It is further possible to investigate the abil-
ity of a target to compete with other compounds and to look 
at the effects of changing the reaction conditions, the structure 
of the binding agent, or the type of target. Other methods that 
have been used with affinity microcolumns include peak de-
Figure 12. (a) Chromatograms obtained at several flow rates and (b) 
analysis of the resulting band-broadening data according to Equa-
tion (14) for studies of the dissociation rate of carbamazepine from a 
5 cm × 4.6 mm i.d. HSA column by the peak profiling method. Repro-
duced with permission from Reference [194].
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cay analysis, ultrafast affinity extraction and split-peak anal-
ysis. The possible use of band-broadening measurements and 
peak profiling with affinity microcolumns was discussed as 
well. These techniques can provide data on the association/
dissociation rates of a biomolecular interaction and can probe 
the binding of a target with a soluble binding agent.
The potential advantages and versatility of affinity micro-
columns make them attractive tools for biochemical analysis. 
This is illustrated by the diverse group of applications that has 
already been reported for affinity microcolumns in the anal-
ysis of biomolecular interactions. Applications that were de-
scribed in this report included studies on the interactions of 
pharmaceutical agents with serum proteins, the binding of an-
tibodies with their targets and antibody proteins, the screen-
ing of libraries for potential enzyme inhibitors, and the bind-
ing of lectins with sugars. As further developments appear in 
the design and use of affinity microcolumns, it is expected that 
these columns and their associated techniques will continue to 
grow in importance as means for examining biomolecular in-
teractions in biomedical and pharmaceutical research.
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